Analysts predict that NuCana PLC (NASDAQ:NCNA) will post earnings per share of ($0.12) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for NuCana’s earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.12). The firm is scheduled to issue its next earnings results on Monday, January 1st.
Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover NuCana.
Several equities analysts have commented on NCNA shares. Zacks Investment Research upgraded shares of NuCana from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday, January 10th. Citigroup started coverage on NuCana in a research report on Monday, October 23rd. They set a “buy” rating and a $23.00 price objective for the company. Jefferies Group started coverage on NuCana in a research report on Monday, October 23rd. They set a “buy” rating and a $25.00 price objective for the company. William Blair started coverage on NuCana in a research report on Monday, October 23rd. They set an “outperform” rating for the company. Finally, Cowen started coverage on NuCana in a research report on Monday, October 23rd. They set an “outperform” rating for the company. Five investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $21.00.
NuCana (NASDAQ NCNA) traded up $6.02 during trading on Friday, hitting $20.51. 956,318 shares of the stock traded hands, compared to its average volume of 57,491. NuCana has a 12-month low of $9.32 and a 12-month high of $25.68.
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.